[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibiotic-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibiotic-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,75,110,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":45},"100640645","phase-2-multicenter-phase-ii-trial-of-nricm102-combined-with-standard-therapy-in-pneumonia-100640645",false,"NCT07583992","Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia","Inclusion Criteria:\n\n1. Male or female subjects aged 18 to 85 years\n2. The subjects are diagnosed with community-acquired pneumonia (CAP) at the time of hospital admission and must meet all of the following criteria:\n\n   Chest X-ray showing new onset or persistent pulmonary infiltrate At least two of the following abnormal clinical or laboratory findings: (a) Cough, (b) Sputum production, (c) Fever (≥37.8℃) or hypothermia (\\\u003C35℃), (d) Auscultatory findings of rales or bronchial breath sounds, (e) White blood cell count greater than 10×10⁹\u002FL or less than 4×10⁹\u002FL\n3. Subjects requiring hospitalization and intravenous antibiotic therapy\n4. Subjects who have received standard antibiotic therapy for less than 24 hours after hospital admission\n5. Subjects who are able to take the investigational product orally\n6. Subjects who are able to understand and comply with all study procedures and provide written informed consent\n\nExclusion Criteria:\n\n1. Subjects who have received systemic antibiotic treatment within 72 hours prior to screening; routine antibiotics administered after hospital admission are not included in this restriction\n2. Subjects who have used oral traditional Chinese medicine (TCM) or traditional Chinese medicine preparations that may affect efficacy assessment within 7 days prior to hospital admission\n3. Subjects who have been hospitalized within 15 days prior to current admission\n4. Subjects with aspiration pneumonia\n5. Subjects requiring admission to the intensive care unit (ICU)\n6. Subjects requiring hemodialysis\n7. Subjects with any malignancy, except those who have completed curative treatment with no signs of recurrence for more than five years and require no further anticancer therapy (based on medical history)\n8. Subjects with human immunodeficiency virus (HIV) infection\n9. Subjects requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), steroids, or other immunosuppressants\n10. Subjects requiring antiviral agents for COVID-19 infection or influenza\n11. Subjects must be on a stable dose of Omeprazole or Warfarin\n12. Subjects with alcohol or substance abuse, or other major organic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, tuberculosis (TB), or significant heart, kidney, or other major organ dysfunction or failure (based on medical history)\n13. Female subjects who are pregnant, breastfeeding, or of childbearing potential, or those intending to become pregnant between the signing of the Informed Consent Form (ICF) and the final observation\u002Fstudy time point, or who are unwilling to use an appropriate method of contraception. Acceptable highly effective methods of contraception include:\n\n    1. Surgical sterilization (male or female), contraceptive implants, or intrauterine devices (IUDs).\n    2. Injectable contraceptives, oral contraceptives, contraceptive patches, or vaginal rings, used in combination with one barrier method.\\*\n    3. Combination of two barrier methods.\\* \\*Effective barrier methods include diaphragms, male or female condoms, contraceptive sponges, or spermicides (creams or gels containing spermicidal chemicals).\n14. Subjects deemed unsuitable for study participation by the investigator","ALL","18 Years","85 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to learn if NRICM102 (a Traditional Chinese Medicine) works to treat community-acquired pneumonia (CAP) in adults when added to standard antibiotic therapy. It will also learn about the safety of NRICM102. The main questions it aims to answer are:\n\n1. Does NRICM102 help participants reach clinical stability faster compared to placebo?\n2. What medical problems do participants have when taking NRICM102?\n\nResearchers will compare NRICM102 to a placebo (a look-alike substance that contains no drug) to see if NRICM102 works as an add-on treatment for community-acquired pneumonia.\n\nParticipants will:\n\n1. Take NRICM102 or a placebo (2 sachets, 3 times daily) in addition to standard intravenous antibiotic treatment for 7 days\n2. Be hospitalized and visited by the study team on Day 1, Day 4, and Day 8 for vital sign monitoring, symptom assessments, laboratory tests, and chest X-ray examinations\n3. Be contacted by telephone on Day 30 to check if they were readmitted to the hospital after discharge",[26,27,28,29,30],"Mild to Moderate","Community-Acquired Pneumonia (CAP)","Antibiotic Therapy","Intravenous","Hospitalisation",[32,27,33],"NRICM102","National Research Institute of Chinese Medicine, Ministry of Health and Welfare","NOT_YET_RECRUITING","2026-05-07",{"date":37,"type":38},"2026-05-13","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2027-11",{"name":33,"class":44},"OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100622160","acceptability-and-adherence-to-different-dosing-regimens-of-the-multistrain-probiotic-vivomixx-460-neo-9-in-adults-receiving-antibiotic-therapy-100622160","NCT07380009","Acceptability and Adherence to Different Dosing Regimens of the Multistrain Probiotic Vivomixx® 460 Neo 9 in Adults Receiving Antibiotic Therapy.","Acceptability and Adherence to Different Dosing Regimens of the Multistrain Probiotic Vivomixx® 460 Neo 9 in Adults Receiving Antibiotic Therapy: a Randomized, Open-label Clinical Trial.","VIVOMIXX 460","Inclusion Criteria:\n\n* Men and women aged over 18 years\n* Initiation of oral antibiotic therapy lasting more than 3 days\n* History of diarrhea during previous antibiotic treatment\n* Eligible antibiotics include: (a) amoxicillin with clavulanic acid, (b) clindamycin, and (c) second- or third-generation cephalosporins\n* Willingness to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Age under 18 years\n* Diagnosis of a chronic autoimmune disease (e.g., Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis)\n* Diagnosis of type I or type II diabetes\n* Renal or hepatic disease\n* Current use of immunosuppressive medications\n* Current use of other supplements, probiotics, prebiotics, or synbiotics\n* Use of antibiotics within the past month\n* Use of laxatives or antidiarrheal medications within the past 2 weeks\n* Pre-existing diarrhea within the past 2 weeks\n* Self-reported allergy to any component of the probiotic\n* Psychological conditions affecting the ability to provide informed consent (e.g., dementia, psychosis, substance use)\n* Gastrointestinal surgery within the past 6 months",{"count":55,"type":20},40,[57],"NA","This open-label interventional study aims to evaluate the acceptability and adherence of adult participants to the multistrain probiotic Vivomixx® 460 Neo 9 when administered concurrently with antibiotic therapy. Participants are randomized to receive one of two dosing regimens: a low daily dose or a high daily dose. The study will assess the effects of these regimens on the prevention of antibiotic-associated diarrhea (AAD), gastrointestinal symptoms, and patient adherence and acceptability. The results are intended to provide evidence to optimize the clinical use of probiotics alongside antibiotics.",[28],[61,62,63],"antibiotic","probiotic","vivomixx","RECRUITING","2026-01-23",{"date":67,"type":38},"2026-02-02",{"date":69,"type":38},"2025-12-12",{"date":71,"type":20},"2026-05-30",{"name":73,"class":74},"University of Thessaly","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":45},"100593985","oritavancin-for-cied-infections-with-mdr-gram-positive-cocci-100593985","NCT07013552","Oritavancin for CIED Infections With MDR Gram-positive Cocci","Oritavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections With Multidrug-resistant Gram-positive Cocci","ORI-4-CIEDi","Inclusion Criteria:\n\n1. Completed 18 years of age\n2. Presence of signs and symptoms of superficial ABSSSI or PI in the form of a) redness\u002Fwarmth\u002Fswelling\u002Fpain or b) separation of the edges of the surgical incision with signs of inflammation or the need for repeated surgical debridement of the wound or c) the presence of decubitus of the skin and subcutaneous tissue in area of the generator or skin abscess\u002Ferosion of the device pocket, with purulent discharge from the wound or discharge giving a positive microbial culture\n3. Probable\u002F definite diagnosis of right-sided LRIE according to modified Dukes criteria (optional criterion)\n4. Suspected\u002Fconfirmed infection with drug-resistant Gram-positive cocci, i.e., Staphylococcus spp. (Stahphylococcus aureus or coagulase-negative staphylococci), Streptococcus spp. or Enterococcus spp. sensitive to oritavancin\n5. Suspected\u002Fconfirmed infection with Gram-positive cocci, i.e., Staphylococcus spp., Streptococcus spp., Enterococcus spp., sensitive to vancomycin or oritavancin and beta-lactam antibiotics in patients with a history of type I anaphylaxis to penicillin.\n\nExclusion Criteria:\n\n1. Suspected\u002Fconfirmed infection with Gram-positive or Gram-negative bacilli or anaerobic bacteria\n2. Suspected\u002Fconfirmed community-acquired infection or infection with Gram-positive cocci sensitive to betalactam antibiotics, including penicillin, ampicillin, or methicillin, based on empirical data or cultures (does not apply to patients with a history of type I anaphylaxis to penicillin)\n3. Confirmed resistance of Gram-positive cocci, which are the etiological factor of the infection, to vancomycin and oritavancin.\n4. History of hypersensitivity to oritavancin or another lipoglycopeptide antibiotic (applies to the experimental group only)\n5. History of hypersensitivity to vancomycin or another glycopeptide antibiotics (applies to the control group only)\n6. No possibility of temporarily interrupting\u002Finitiating alternative therapy to intravenous infusion of unfractionated heparin\n7. Pregnancy or breastfeeding\n8. Lack of informed written consent of the patient to participate in the study",{"count":84,"type":20},100,[57],"The study aimed to conduct a randomized, non-inferiority controlled trial to compare the short- and medium-term efficacy and safety of two antibiotic dosage regimens in cardiac implantable electronic devices (CIED) infections with multidrug-resistant Gram-positive cocci: 1) single-dose therapy with a long-half-life antibiotic (oritavancin) vs. standard 7-14 days of therapy with a short-half-life antibiotic (vancomycin) for CIED surgical incision site or pocket infection; and 2) fractionated therapy with a long-half-life antibiotic (oritavancin) at seven-day intervals compared to standard therapy with a short-half-life antibiotic (vancomycin) fractionated in 2-3 daily doses in cases of lead-related infectious endocarditis.",[88,89,90,91,92,28,93],"Cardiac Implantable Electronic Device Infections","Infective Endocarditis","Multidrug-resistant Bacteria Screening","Gram Positive Bacterial Infection","Antibiotic Resistant Strain","Healthcare Associated Infections",[95,96,97,98,99,100],"Cardiac implantable electronic device","Gram-positive cocci","Health-care associated infections","Lead-related infective endocarditis","Multidrug-resistant bacteria","Pocket infection","2025-06-02",{"date":103,"type":38},"2025-06-10",{"date":105,"type":20},"2025-06",{"date":107,"type":20},"2026-10",{"name":109,"class":74},"Medical University of Silesia",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":15,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100592084","phase-4-comparison-of-g-csf--antibiotics-versus-antibiotics-alone-in-resolution-of-febrile-neutropenia-100592084","NCT06988826","Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia","Comparison of Antibiotics With and Without Granulocyte Colony-Stimulating Factor in Children With Chemotherapy Induced Febrile Neutropenia","AGF-FN","Inclusion Criteria:\n\n* Age 1-16 years\n* any Gender\n* Febrile neutropenia\n* diagnosed case of solid or hematological malignancy\n* taking chemotherapy\n\nExclusion Criteria:\n\n* Non-neutropenic fever\n* already received G-CSF or antibiotics before presenting to hospital\n* any other cause of neutropenia","1 Year","16 Years",{"count":19,"type":20},[122],"PHASE4","This study aim to find the best option for children having cancer who develop low immunity state due to chemotherapy",[125,126,127,128,28],"Febrile Neutropenia","Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy","Febrile Neutropenia, Drug-Induced","G-CSF",[130,131,132,128],"febrile neutropenia","chemotherapy-induced febrile neutropenia","Antibiotics","2025-05-23",{"date":135,"type":38},"2025-05-25",{"date":137,"type":20},"2025-06-01",{"date":139,"type":20},"2026-12",{"name":141,"class":74},"King Edward Medical University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100467457","therapeutic-monitoring-of-antibiotics-in-intensive-care-patients-a-cohort-study-poptdm-icu-100467457","NCT05367011","Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU","Etude de Cohorte de Suivi thérapeutique de l'antibiothérapie Chez Les Patients de réanimation","Inclusion Criteria:\n\n* Patient ≥ 18 year-old.\n* Patient hospitalized in intensive care,\n* Patient receiving an antibiotic for sepsis or septic shock\n* Patient or family member who does not object to participating in the study\n\nExclusion Criteria:\n\nPatient at risk of death, for a cause other than infectious, within 48 hours following the introduction of antibiotic therapy.\n\n* Patient receiving antibiotic treatment for antibiotic prophylaxis.\n* Patients benefiting from enhanced protection, namely: minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection.\n* Pregnant and \u002F or lactating women.",{"count":150,"type":20},2500,"OBSERVATIONAL","Intensive care patients are exposed to serious infections. Mortality linked to these infections remains high and antibiotic therapy treatment optimization is one of the key points of therapeutic success . Pharmacokinetic therapeutic monitoring and dosage adjustments are recommended for large families of antibiotics such as glycopeptides and aminoglycosides for a long time, but to this day still insufficiently practiced. Concerning Beta-Lactamines this practice is recommended by french society of pharmacology and therapeutic (SFPT) and french society of anesthesiology and intensive care (SFAR) since 2018.\n\nThe main goal of the POP-TDM-ICU study is to find the predictive factors of clinical therapeutic efficacy of antibiotic therapy in sepsis or septic shock in intensive care, among which the use of the dosage pharmacokinetics of antibiotic therapy (TDM = Therapeutic Drug Monitoring).\n\nThis study is a non-interventional study. Patients bacterial samples already collected in standard care and additional plasma samples will be collected as part of a biological collection with the consent of the patient or family member.",[154,28,155],"Intensive Care Unit","Pharmacokinetic",[157,158,159],"Antibiotic","Intensive care","Therapeutic drug monitoring","2022-08-03",{"date":162,"type":38},"2022-08-04",{"date":164,"type":20},"2022-09-01",{"date":166,"type":20},"2028-09-01",{"name":168,"class":74},"Poitiers University Hospital"]